Quantinno Capital Management LP Has $3.93 Million Stake in Ultragenyx Pharmaceutical Inc. $RARE

Quantinno Capital Management LP grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 276.9% in the first quarter, Holdings Channel reports. The institutional investor owned 187,508 shares of the biopharmaceutical company’s stock after purchasing an additional 137,758 shares during the period. Quantinno Capital Management LP’s holdings in Ultragenyx Pharmaceutical were worth $3,928,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $10,973,000. BNP Paribas Financial Markets lifted its position in shares of Ultragenyx Pharmaceutical by 57.6% in the 4th quarter. BNP Paribas Financial Markets now owns 903,050 shares of the biopharmaceutical company’s stock worth $20,770,000 after acquiring an additional 330,031 shares during the period. GW&K Investment Management LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 19.6% during the 4th quarter. GW&K Investment Management LLC now owns 1,375,407 shares of the biopharmaceutical company’s stock worth $31,634,000 after purchasing an additional 225,238 shares in the last quarter. UBS Group AG grew its holdings in shares of Ultragenyx Pharmaceutical by 22.3% during the 4th quarter. UBS Group AG now owns 668,811 shares of the biopharmaceutical company’s stock worth $15,383,000 after purchasing an additional 121,786 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Ultragenyx Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock valued at $236,068,000 after purchasing an additional 131,087 shares during the period. Institutional investors own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RARE. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday. Guggenheim decreased their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday. Wells Fargo & Company lowered their price target on shares of Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday. Cantor Fitzgerald increased their price objective on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research note on Thursday, May 21st. Finally, Wedbush reduced their price objective on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $57.82.

Ultragenyx Pharmaceutical Trading Up 0.3%

Shares of RARE opened at $25.91 on Friday. The stock has a market cap of $2.55 billion, a PE ratio of -4.44 and a beta of 0.35. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.29 and a 1 year high of $39.89. The stock has a 50 day simple moving average of $27.89 and a 200-day simple moving average of $24.80.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the previous year, the firm earned ($1.17) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 28.5% on a year-over-year basis. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.46 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Shehnaaz Suliman sold 5,740 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the sale, the director owned 27,951 shares of the company’s stock, valued at approximately $702,129.12. This represents a 17.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the sale, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. This trade represents a 8.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 14,292 shares of company stock valued at $351,644 in the last ninety days. Insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.